Atlanta – what’s exactly behind a poster board mobbing at AACR?
AACR19 Poster Hall
Is there some science or rationale behing the attention or is it something quite quirky and unexpected?
That was the critical question we wondered about as we traversed the poster hall sessions over the last few days and noticed the certain posters received more attention than others:
- Why was this?
- Is there a rhyme and reason to it?
- Which ones were actually mobbed?
- Is the attention justified?
If you’re curious like we were, then this is the post for you.
We highlight several posters from the AACR19 conference that received a noticeable amount of traffic and in future posts we will highlight those we consider to be gems from the poster halls and explain why, which… wasn’t necessarily quite the same thing (as being mobbed).
So without much ado, which ones were in the spotlight by AACR attendees this year?
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Autumn leaves in Munich
We have increasingly seen how oncologists like the efficacy associated with the immune checkpoint combination of ipilimumab plus nivolumab, but are leery of the increase in side effects, including immune related events.
Are there practical ways to reduce this phenomenon, other than dose reductions?
CytomX are one company who are focused on engineering a different concept with their monoclonal antibodies, bispecifics and ADCs to try and mask the effects, thereby reducing the treatment emergent toxicities. Their main idea is that the therapeutic window can be widened, thereby improving the tolerability profile.
It’s a nice idea, but what happens in practice?
To find out, we took a look at the recent early clinical data and interviewed executives from the company…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.